Analysts for Stifel and BTIG launched coverage of Rani Therapeutics (NASDAQ:RANI) with “buy” ratings and price targets of $24, respectively. The stock closed at $17.76 on Aug. 24. “Rani appears to have cracked the...
Analysts for BTIG and SVB Leerink launched coverage of RxSight (NASDAQ:RXST) with “buy” ratings and price targets of $28 and $20, respectively. The stock closed at $11.94 on Aug. 23. RxSight has developed the Light...
William Blair launched coverage of Icosavax (NASDAQ:ICVX) with an “outperform” rating. The stock closed at $34.09 on Aug. 20. “We believe Icosavax stands to benefit from both the medical and investment communities’...
H.C. Wainwright launched coverage of IVERIC Bio (NASDAQ:ISEE) with a “buy” rating and price target of $20. The stock closed at $9.07 on Aug. 18. Analyst Matthew Caufield writes that IVERIC’s retinal platform...
Alliance Global Partners downgraded IMAC Holdings (NASDAQ:IMAC) to “neutral” and reduced its price target to $1.75 from $2.35 after the Center for Medicare and Medicaid Services (CMS) requested repayment of $2.9-million...
SVB Leerink initiated coverage of Amryt Pharma PLC (NASDAQ:AMYT) with an “outperform” rating and price target of $22. Analyst Mani Foroohar, M.D., writes that Amryt’s model of acquiring niche commercial or near...
Cantor Fitzgerald launched coverage of Portage Biotech (NASDAQ:PRTG) with an “overweight” rating and $35 price target. The stock closed at $18.95 on Aug. 18. Portage Biotech is a clinical biopharmaceutical company...
Cantor Fitzgerald upgraded MedMen Enterprises (OTCQB:MMNFF) to a “neutral” rating from “underweight” with a new price target of 30 cents after Tilray (NASDAQ:TLRY) purchased a 21% contingent stake in MedMen for $118...
Echelon Capital Markets raised its price target for Diagnos (TSXV:ADK) to $1.55 (Canadian) from 95 cents after it signed a memorandum of understanding (MoU) for a potential worldwide distribution agreement for its CARA...
Raymond James upgraded HLS Therapeutics (TSX:HLS) to “outperform” from “market perform” and raised its price target to $26 (Canadian) from $24 after Pfizer agreed to co-market HLS’s cardiovascular drug...